Exercise of Warrants and Issue of Equity

RNS Number : 1752A
OptiBiotix Health PLC
10 September 2018
 

OptiBiotix Health plc

("OptiBiotix")

 

Exercise of Warrants and Issue of Equity

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol and diabetes, has received a notification for the exercise of warrants over 166 ordinary shares in the Company at an exercise price of 8 pence per share providing the Company with proceeds of £13.28.

 

Application will be made to the London Stock Exchange to admit the 166 new ordinary shares to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 13 September 2018. The new ordinary shares will rank pari passu with the existing ordinary shares.

 

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 84,366,641 ordinary shares of 2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive Officer.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

 

finnCap (Broker)

 

Tel: 020 7220 0500

Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance)

 

Camille Gochez (Corporate Broking)

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

Lianne Cawthorne

Mob: 07584 391 303

     

 

 

 

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

 

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCZMGGLDNGGRZM
UK 100

Latest directors dealings